Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma

IJU Case Reports

article

Takuya Iwaki¹  Aya Niimi¹  Masato Kano¹  Yoshiaki Kurokawa³  Uran Yoshizaki¹  Keina Nozaki¹  Akira Nomiya¹  Hideyo Miyazaki¹  Haruki Kume³ 

[1] Department of Urology, Center Hospital of the National Center for Global Health and Medicine;Department of Urology, New Tokyo Hospital;Department of Urology, The University of Tokyo Hospital

关键词: dialysis;    end-stage renal disease;    immune checkpoint inhibitor;    ipilimumab;    nivolumab;    renal cell carcinoma;   

DOI  :  10.1002/iju5.12231

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction The combination of ipilimumab plus nivolumab has been used as first-line therapy for metastatic renal cell carcinoma. While it is well known that hemodialysis patients have a higher rate of renal cell carcinoma compared to the general population, no reports have described the safety of ipilimumab–nivolumab in metastatic renal cell carcinoma patients on hemodialysis. Case presentation A 73-year-old man with a 21-year history of dialysis was referred to our department in 2019 for bilateral renal tumors and multiple lung nodules. He had already been diagnosed with bilateral renal tumors in 2015, without undergoing surgery due to comorbidities. In May 2019, contrast-enhanced computed tomography revealed multiple lung metastases in addition to the existing renal tumors; consequently, he was treated with four doses of nivolumab–ipilimumab with no adverse events. Conclusion The combination of ipilimumab plus nivolumab was safely used in a hemodialysis patient with metastatic renal cell carcinoma.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND